BioMarin Pharmaceutical Inc.
DE ˙ DB ˙ US09061G1013
46,59 € ↑0,90 (1,97%)
2026-06-04
AKTIENPREIS
SecurityDE:BM8 / BioMarin Pharmaceutical Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership689,721 shares
Latest Disclosed Value $ 38,962,339
Qube Research & Technologies Ltd ownership in BM8 / BioMarin Pharmaceutical Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 689,721 shares of BioMarin Pharmaceutical Inc. (DE:BM8) valued at $33,092,814 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,436,639 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of -51.99% during the quarter. The current value of the position is $32,134,101 USD.

Qube Research & Technologies Ltd has a history of taking positions in derivatives of the underlying security (BM8) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:BM8 / BioMarin Pharmaceutical Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 689,721 -746,918 -51.99 38,962 -54.37 0.0433
2026-02-17 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 1,436,639 1,176,410 452.07 85,379 505.78 0.0867
2025-11-14 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 260,229 -380,164 -59.36 14,094 -59.96 0.0146
2025-08-14 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 640,393 640,393 35,202 0.0358
2025-05-15 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -6,576 -100.00 0 -100.00
2025-02-14 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 6,576 6,576 432 0.0006
2024-11-14 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -14 -100.00 0 -100.00
2024-08-14 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 14 -14,835 -99.91 1 -99.92 0.0000
2024-05-14 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 14,849 4,319 41.02 1,297 27.68 0.0021
2024-02-13 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 10,530 -71,145 -87.11 1,015 -85.95 0.0020
2023-11-13 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 81,675 -407,530 -83.30 7,227 -82.96 0.0189
2023-08-14 2023-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 489,205 12,454 2.61 42,404 -8.53 0.1542
2023-05-15 2023-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 476,751 211,481 79.72 46,359 68.87 0.1994
2023-02-14 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 265,270 169,933 178.24 27,453 239.67 0.1470
2022-11-14 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 95,337 95,337 8,082 0.0481
2022-08-15 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -268,780 -100.00 0 -100.00
2022-05-09 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 268,780 268,780 20,723 0.1756
2022-02-10 2021-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 0 -24,205 -100.00 0 -100.00
2022-02-01 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -24,205 0
2021-11-12 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 24,205 10,252 73.48 1,871 60.74 0.0235
2021-08-13 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 13,953 3,197 29.72 1,164 43.35 0.0133
2021-05-14 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 10,756 10,756 812 0.0129
2021-02-16 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -52,118 -100.00 0 -100.00
2020-11-12 2020-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 52,118 45,906 738.99 3,965 417.62 0.0566
2020-08-14 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 6,212 6,212 766 0.0112
2019-11-13 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -6,387 -100.00 0 -100.00
2019-08-02 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 6,387 2,334 57.59 547 51.94 0.1302
2019-05-15 2019-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,053 4,053 360 0.0475
2019-02-14 2018-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -2,704 -100.00 0 -100.00
2018-11-14 2018-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,704 2,704 262 0.0348
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-08-14 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-14 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM Put 12,100 1,057 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.